Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 12/20 | 0.65 |
| ▸ | LGALS9 | O00182 | 6/20 | 0.65 |
| ▸ | LGALS1 | P09382 | 6/20 | 0.65 |
| ▸ | LGALS7; LGALS7B | P47929 | 5/20 | 0.65 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.51 |
| ▸ | LGALS4 | P56470 | 3/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.44 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17154133 | 0.92 | LGALS3 (0.60) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL17154143 | 0.92 | LGALS3 (0.60) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL19674440 | 0.91 | LGALS3 (0.58) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL19674473 | 0.91 | LGALS3 (0.58) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL5899337 | 0.91 | LGALS3 (0.56) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL16623018 | 0.90 | LGALS3 (0.57) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL7023852 | 0.89 | LGALS3 (0.52) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL7024531 | 0.89 | LGALS3 (0.52) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL5899315 | 0.86 | LGALS3 (0.57) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL19090197 | 0.85 | LGALS3 (0.80) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635685-B2 | Bifunctional antibiotics for targeting rRNA and resistance-causing enzymes and for inhibition of anthrax lethal factor | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2009-12-22 | — | — | US | disclosed |
| EP-1789429-B1 | BIFUNCTIONAL ANTIBIOTICS FOR TARGETING RRNA AND RESISTANCE CAUSING ENZYMES AND FOR INHIBITION OF ANTHRAX LETHAL FACTOR | TECHNION RES & DEV FOUNDATION (IL) | 2009-08-26 | — | — | EP | disclosed |
| EP-1789429-A2 | BIFUNCTIONAL ANTIBIOTICS FOR TARGETING RRNA AND RESISTANCE CAUSING ENZYMES AND FOR INHIBITION OF ANTHRAX LETHAL FACTOR | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION, LTD. (IL) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006027784-A2 | BIFUNCTIONAL ANTIBIOTICS FOR TARGETING RRNA AND RESISTANCE CAUSING ENZYMES AND FOR INHIBITION OF ANTHRAX LETHAL FACTOR | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2006-03-16 | — | — | WO | disclosed |
| US-20050148522-A1 | Bifunctional antibiotics for targeting rRNA and resistance-causing enzymes and for inhibition of anthrax lethal factor | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. | 2005-07-07 | — | — | US | disclosed |
| US-20050004052-A1 | Bifunctional antibiotics for targeting rRNA and resistance-causing enzymes | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148522-A1 | Bifunctional antibiotics for targeting rRNA and resistance-causing enzymes and for inhibition of anthrax lethal factor | ANTXR2, RNASEH1, RNASEL | LGALS3 3941/4885LGALS9 3185/4885LGALS1 3490/4885 |
| US-20050004052-A1 | Bifunctional antibiotics for targeting rRNA and resistance-causing enzymes | EMG1, FBL, RRM2B | LGALS3 4310/4885LGALS9 4004/4885LGALS1 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.